- Home
- THCH vs CNTX Comparison
THCH vs CNTX Comparison
Compare THCH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THCH | CNTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | China | United States |
| Employees | 1580 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 57.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | THCH | CNTX |
|---|---|---|
| Price | $1.63 | $0.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 6.1K | ★ 1.6M |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $0.48 |
| 52 Week High | $3.25 | $3.62 |
Technical Indicators
Market Signals| Indicator | THCH | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 29.15 |
| Support Level | $1.24 | N/A |
| Resistance Level | $1.99 | $0.68 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 33.33 | 7.61 |
Price Performance
Historical ComparisonAbout THCH TH International Limited Ordinary shares
TH International Ltd is the exclusive master franchisee in China for Tim Hortons, a world-wide coffee and bakery shop brand. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under a single reportable segment, Tim Hortons. The company's revenue is derived from sales of food, beverages, and packaged products by company-owned and operated stores, franchise fees, and revenue from other franchise support activities. Its geographic revenue is derived from operations in the PRC.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.